ACGN Stock Overview
Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Aceragen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.65 |
| 52 Week High | US$16.00 |
| 52 Week Low | US$3.66 |
| Beta | 1.3 |
| 1 Month Change | -53.18% |
| 3 Month Change | -16.91% |
| 1 Year Change | -39.03% |
| 3 Year Change | -79.10% |
| 5 Year Change | -97.85% |
| Change since IPO | -99.99% |
Recent News & Updates
Idera Pharmaceuticals completes acquisition of Aceragen
Sep 28We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Aug 24
Recent updates
Idera Pharmaceuticals completes acquisition of Aceragen
Sep 28We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Aug 24We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully
May 11Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?
Mar 07When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?
Jan 31Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma
Jan 13Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?
Dec 27Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
Dec 27Idera Pharmaceuticals receives $5M in additional proceeds from private placement
Dec 15We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Nov 25Idera Pharma names new operations chief
Nov 17Idera Pharmaceuticals EPS misses by $0.37
Oct 29Shareholder Returns
| ACGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 12.9% | -0.8% | 1.7% |
| 1Y | -39.0% | 4.3% | -9.6% |
Return vs Industry: ACGN underperformed the US Biotechs industry which returned 4.3% over the past year.
Return vs Market: ACGN underperformed the US Market which returned -9.6% over the past year.
Price Volatility
| ACGN volatility | |
|---|---|
| ACGN Average Weekly Movement | 24.8% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ACGN is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 25% a week.
Volatility Over Time: ACGN's weekly volatility has increased from 17% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 13 | John Taylor | https://www.aceragen.com |
Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701 for acute pulmonary exacerbations in cystic fibrosis, as well as for melioidosis; and ACG-801 for farber disease. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023.
Aceragen, Inc. Fundamentals Summary
| ACGN fundamental statistics | |
|---|---|
| Market Cap | US$47.81m |
| Earnings (TTM) | -US$16.22m |
| Revenue (TTM) | US$49.00k |
975.6x
P/S Ratio-2.9x
P/E RatioIs ACGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACGN income statement (TTM) | |
|---|---|
| Revenue | US$49.00k |
| Cost of Revenue | US$9.25m |
| Gross Profit | -US$9.20m |
| Other Expenses | US$7.02m |
| Earnings | -US$16.22m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.92 |
| Gross Margin | -18,771.43% |
| Net Profit Margin | -33,095.92% |
| Debt/Equity Ratio | 0% |
How did ACGN perform over the long term?
See historical performance and comparison